Bullock-Palmer Renee P, Bravo-Jaimes Katia, Mamas Mamas A, Grines Cindy L
Department of Cardiology, Deborah Heart and Lung Center Browns Mills, NJ, US.
Division of Cardiology, Department of Internal Medicine, Ahmanson/UCLA Adult Congenital Heart Disease Center, University of California Los Angeles, CA, US.
Eur Cardiol. 2022 Oct 27;17:e19. doi: 10.15420/ecr.2022.23. eCollection 2022 Feb.
In the past few decades, the accelerated improvement in technology has allowed the development of new and effective coronary and structural heart disease interventions. There has been inequitable patient access to these advanced therapies and significant disparities have affected patients from low socioeconomic positions. In the US, these disparities mostly affect women, black and hispanic communities who are overrepresented in low socioeconomic. Other adverse social determinants of health influenced by structural racism have also contributed to these disparities. In this article, we review the literature on disparities in access and use of coronary and structural interventions; delineate the possible reasons underlying these disparities; and highlight potential solutions at the government, healthcare system, community and individual levels.
在过去几十年中,技术的加速进步推动了新型有效冠状动脉和结构性心脏病干预措施的发展。患者在获取这些先进治疗方法方面存在不公平现象,社会经济地位较低的患者受到了显著影响。在美国,这些差异主要影响社会经济地位较低群体中占比过高的女性、黑人和西班牙裔社区。结构性种族主义影响下的其他不良健康社会决定因素也导致了这些差异。在本文中,我们回顾了关于冠状动脉和结构性干预措施的获取与使用差异的文献;阐述了这些差异背后可能的原因;并强调了政府、医疗保健系统、社区和个人层面的潜在解决方案。